Pfizer Inc.’s Price-to-Earnings Ratio at a glance
Pfizer Inc. reports price-to-earnings ratio of 18.7x for Dec 2024. The prior period recorded 76.2x (Dec 2023). Year over year the metric moved −57.43 (−75.4%). The rolling three-period average stands at 34.7x. Data last refreshed Dec 7, 2025, 2:46 AM.
Latest reading
18.7x · Dec 2024
YoY movement
−57.43 (−75.4%)
Rolling average
34.7x
Current Price-to-Earnings Ratio
18.7x
−57.43
−75.4%
Rolling average
34.7x
Latest Value
18.7x
Dec 2024
YoY Change
−57.43
Absolute
YoY Change %
−75.4%
Rate of change
3-Period Avg
34.7x
Smoothed
Narrative signal
Pfizer Inc.’s price-to-earnings ratio stands at 18.7x for Dec 2024. Year-over-year, the metric shifted by −57.43, translating into a −75.4% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How price-to-earnings ratio shapes Pfizer Inc.'s story
As of Dec 2024, Pfizer Inc. reports price-to-earnings ratio of 18.7x. Analyze price-to-earnings history, valuation swings, and relative multiples to benchmark market expectations.
Why the P/E ratio matters
The price-to-earnings multiple reveals how much investors are willing to pay for each dollar of net income. Elevated P/E levels suggest strong growth expectations or limited earnings.
Tracking valuation cycles
Monitoring multi-year P/E trends highlights how macro cycles, product launches, or profitability changes impact valuation over time.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Gross Margin
65.8%
Operating Margin
25.9%
Net Profit Margin
12.6%
Return on Equity
9.1%
Return on Assets
3.8%
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Pfizer Inc. (PFE) FAQs
Answers tailored to Pfizer Inc.’s price-to-earnings ratio profile using the latest Financial Modeling Prep data.
What is Pfizer Inc.'s current price-to-earnings ratio?
As of Dec 2024, Pfizer Inc. reports price-to-earnings ratio of 18.7x. This reading reflects the latest filings and price data for PFE.
How is Pfizer Inc.'s price-to-earnings ratio trending year over year?
Year-over-year, the figure shifts by −57.43 (−75.4%). Pair this context with revenue growth and free cash flow signals to gauge momentum for PFE.
Why does price-to-earnings ratio matter for Pfizer Inc.?
The P/E ratio compares a company’s share price with its per-share earnings to gauge valuation. For Pfizer Inc., operating within Healthcare — Drug Manufacturers - General, tracking this metric helps benchmark management's execution against close competitors.
Is Pfizer Inc.'s price-to-earnings ratio above its recent average?
Pfizer Inc.'s rolling three-period average sits at 34.7x. Comparing the latest reading of 18.7x to that baseline highlights whether momentum is building or fading for PFE.
How frequently is Pfizer Inc.'s price-to-earnings ratio refreshed?
Data for PFE was last refreshed on Dec 7, 2025, 2:46 AM and updates automatically every 24 hours, keeping your valuation inputs current.